Welcure Drugs & Pharmaceuticals Ltd Stock Price Today (NSE: WELCURE)
Fundamental Score
Welcure Drugs & Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Welcure Drugs & Pharmaceuticals Ltd share price today is ₹0.28, up +0.00% on NSE/BSE as of 22 June 2026. Welcure Drugs & Pharmaceuticals Ltd (WELCURE) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹67.97 (Cr). The 52-week high for WELCURE share price is ₹15.89 and the 52-week low is ₹0.23. At a P/E ratio of 1.98x, WELCURE is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 4.18% and a debt-to-equity ratio of 0.92.
Welcure Drugs & Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Welcure Drugs & Pharmaceuticals Ltd share price chart: -9.68% return over the past month. 52-week high ₹15.89, 52-week low ₹0.23.
Welcure Drugs & Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹0.28 | ₹0.28 | ₹0.27 | ₹0.28 | 43.61L (Cr) | |
| ₹0.29 | ₹0.29 | ₹0.28 | ₹0.28 | 57.69L (Cr) | |
| ₹0.29 | ₹0.30 | ₹0.28 | ₹0.29 | 60.88L (Cr) | |
| ₹0.28 | ₹0.30 | ₹0.28 | ₹0.29 | 107.46L (Cr) | |
| ₹0.29 | ₹0.30 | ₹0.29 | ₹0.29 | 44.86L (Cr) | |
| ₹0.31 | ₹0.31 | ₹0.30 | ₹0.30 | 51.67L (Cr) | |
| ₹0.31 | ₹0.31 | ₹0.30 | ₹0.31 | 44.00L (Cr) | |
| ₹0.31 | ₹0.31 | ₹0.30 | ₹0.31 | 40.61L (Cr) | |
| ₹0.30 | ₹0.31 | ₹0.30 | ₹0.31 | 39.04L (Cr) | |
| ₹0.30 | ₹0.30 | ₹0.29 | ₹0.30 | 67.44L (Cr) |
Welcure Drugs & Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹0.28 | ₹0.31 | ₹0.27 | ₹0.28 | +0.00% | |
| ₹0.23 | ₹0.36 | ₹0.23 | ₹0.28 | +21.74% | |
| ₹0.30 | ₹0.31 | ₹0.24 | ₹0.24 | -20.00% | |
| ₹0.30 | ₹0.37 | ₹0.28 | ₹0.31 | +3.33% | |
| ₹0.42 | ₹0.46 | ₹0.31 | ₹0.31 | -26.19% | |
| ₹0.53 | ₹0.58 | ₹0.40 | ₹0.42 | -20.75% | |
| ₹0.53 | ₹0.64 | ₹0.50 | ₹0.53 | +0.00% | |
| ₹5.49 | ₹8.45 | ₹0.55 | ₹0.55 | -89.98% | |
| ₹9.36 | ₹10.52 | ₹5.48 | ₹5.50 | -41.24% | |
| ₹9.40 | ₹12.95 | ₹9.26 | ₹9.73 | +3.51% | |
| ₹14.27 | ₹14.99 | ₹9.15 | ₹9.64 | -32.45% | |
| ₹15.88 | ₹15.89 | ₹12.36 | ₹13.60 | -14.36% |
AI Research Briefing
Powered by Gemini · 2026-04-13
Welcure is a micro-cap export sourcing agent with zero promoter stake and negative free cash flow; avoid until fundamentals drastically improve.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The stock price has fluctuated between and
CORE STORY (THE REAL GAME)
Welcure is playing the export-sourcing agent game, earning commissions without balance sheet risk. It's not a pharma innovation play. It's a micro-cap trying to scale fee-based income.
- No recent positive triggers
- Dependence on volatile export orders
- Poor financial metrics (negative FCF, zero promoter holding)
- Significant new export order wins
- Improvement in profitability and cash flow
- Acquisition by a larger player
- Micro/SME cap: Liquidity risk
- Zero promoter holding raises governance concerns
- Negative free cash flow indicates poor cash conversion
No FII or DII holding. Promoter holding is zero.
Indian pharma industry is shifting towards value-led innovation but Welcure's business model is not aligned with this trend.
No: Free Cash Flow 5Y is ₹-222.01 Cr.
Welcure's near-term prospects hinge on securing and executing export orders. Long-term sustainability is doubtful without diversification or improved profitability.
Primary Thesis Risk
Reliance on export orders and lack of promoter stake make Welcure a risky bet.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Welcure Drugs & Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Welcure Drugs & Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of WELCURE across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Attractive Valuation (P/E: 1.98 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (361.96%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (167.29%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (214.33% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (94.95% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (193.83% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (4.18%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (2.53%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Negative Free Cash Flow (₹-222.01 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Welcure Drugs & Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Welcure Drugs & Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Welcure Drugs & Pharmaceuticals LtdWelcure Drugs &...Selected✓ WELCURE • 524661 | 51.9/100 | ₹0.28₹0 | ₹67.97₹67.97 | 1.98Average 2.0 Average | 4.18%Poor 4.18% Poor | 2.53%Poor 2.53% Poor | 0.92Good 0.9 Good | 193.83%Excellent 193.83% Excellent | 214.33%Excellent 214.33% Excellent | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Welcure Drugs & Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for WELCURE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
167.29%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
361.96%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
214.33%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
193.83%
Compounded annual net profit growth over 5 years
Welcure Drugs & Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for WELCURE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Welcure Drugs & Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Welcure Drugs & Pharmaceuticals Ltd (WELCURE) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Welcure Drugs & Pharmaceuticals Ltd
About WELCURE (Welcure Drugs & Pharmaceuticals Ltd)
Welcure Drugs & Pharmaceuticals Ltd is a dynamic player in the Indian pharmaceutical landscape, dedicated to providing access to quality medicines and innovative healthcare solutio...ns. The company operates with a commitment to improving patient outcomes and enhancing the overall well-being of communities. Welcure meticulously sources and distributes a broad spectrum of pharmaceutical products, encompassing various therapeutic areas, to meet the diverse healthcare needs of the nation. Leveraging a robust distribution network and strategic partnerships, Welcure ensures that essential medicines reach healthcare providers and patients efficiently and reliably. Moreover, the company places a strong emphasis on ethical practices, regulatory compliance, and stringent quality control measures throughout its operations, solidifying its reputation as a trusted and responsible pharmaceutical partner. Driven by a vision of contributing to a healthier India, Welcure Drugs & Pharmaceuticals Ltd continually explores opportunities to expand its product portfolio and enhance its service offerings. The company actively seeks collaborations with leading pharmaceutical manufacturers and research institutions to introduce cutting-edge therapies and innovative healthcare technologies to the Indian market. With a customer-centric approach, Welcure prioritizes building strong relationships with healthcare professionals, pharmacies, and other stakeholders to understand their evolving needs and provide tailored solutions. The company's dedicated team of professionals is committed to delivering exceptional service and support, ensuring that healthcare providers have the resources they need to deliver optimal patient care. Welcure Drugs & Pharmaceuticals Ltd is more than just a pharmaceutical distributor; it is a healthcare partner committed to making a positive impact on the lives of people across India. By focusing on quality, innovation, and accessibility, Welcure strives to address the unmet medical needs of the population and improve overall health outcomes. The company's unwavering commitment to ethical business practices, regulatory compliance, and social responsibility makes it a trusted and reliable player in the pharmaceutical industry. As Welcure continues to grow and evolve, it remains steadfast in its mission to contribute to a healthier and more prosperous India, one patient at a time.
Company Details
Key Leadership
Latest News
WELCURE Share Price: Frequently Asked Questions
What is the current share price of Welcure Drugs & Pharmaceuticals Ltd?
Welcure Drugs & Pharmaceuticals Ltd (WELCURE) trades at ₹0.28 on NSE and BSE. Market cap ₹67.97 (Cr). Educational data only.
What is the P/E ratio of Welcure Drugs & Pharmaceuticals Ltd?
Welcure Drugs & Pharmaceuticals Ltd has a P/E of 1.98x vs industry average 31.77x.
What is the Bull Run score for Welcure Drugs & Pharmaceuticals Ltd?
Welcure Drugs & Pharmaceuticals Ltd has a Bull Run score of 51.9/100 based on 25+ financial parameters.
Does Welcure Drugs & Pharmaceuticals Ltd pay dividends?
Welcure Drugs & Pharmaceuticals Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Welcure Drugs & Pharmaceuticals Ltd?
Welcure Drugs & Pharmaceuticals Ltd has ROE of 4.18%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Welcure Drugs & Pharmaceuticals Ltd?
Welcure Drugs & Pharmaceuticals Ltd has debt-to-equity of 0.92.
Is Welcure Drugs & Pharmaceuticals Ltd a good investment?
Bull Run gives Welcure Drugs & Pharmaceuticals Ltd a score of 51.9/100. This is not investment advice — consult a SEBI-registered advisor.